Use of benzodiazepines in obsessive-compulsive disorder

Use of benzodiazepines in obsessive-compulsive disorder

Author Starcevic, Vladan Google Scholar
Berle, David Google Scholar
do Rosario, Maria Conceicao Autor UNIFESP Google Scholar
Brakoulias, Vlasios Google Scholar
Ferrao, Ygor A. Google Scholar
Viswasam, Kirupamani Google Scholar
Shavitt, Roseli Google Scholar
Miguel, Euripedes Google Scholar
Fontenelle, Leonardo F. Google Scholar
Abstract This study aimed to determine the frequency of benzodiazepine (BDZ) use in a large sample of patients with obsessive-compulsive disorder (OCD) and ascertain the type of BDZ used and the correlates and predictors of BDZ use in OCD. The sample consisted of 955 patients with OCD from a comprehensive, cross-sectional, multicentre study conducted by the Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders between 2003 and 2009. The rate of BDZ use over time in this OCD sample was 38.4%. Of individuals taking BDZs, 96.7% used them in combination with other medications, usually serotonin reuptake inhibitors. The most commonly used BDZ was clonazepam. Current age, current level of anxiety and number of additional medications for OCD taken over time significantly predicted BDZ use. This is the first study to comprehensively examine BDZ use in OCD patients, demonstrating that it is relatively common, despite recommendations from treatment guidelines. Use of BDZs in combination with several other medications over time and in patients with marked anxiety suggests that OCD patients taking BDZs may be more complex and more difficult to manage. This calls for further research and clarification of the role of BDZs in the treatment of OCD.
Keywords anxiety
obsessive-compulsive disorder
treatment guidelinesPharmacological-Treatment
Clonazepam Treatment
Panic Disorder
Language English
Sponsor Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Grant number CNPq: 573974/2008-0
FAPESP: 2005/55628-8
Date 2016
Published in International Clinical Psychopharmacology. Philadelphia, v. 31, n. 1, p. 27-33, 2016.
ISSN 0268-1315 (Sherpa/Romeo, impact factor)
Publisher Lippincott Williams & Wilkins
Extent 27-33
Access rights Closed access
Type Article
Web of Science ID WOS:000366691200004

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account